Malaria causes significant adverse pregnancy outcomes, such as maternal anemia, preterm delivery, low birth weight \[[@CIT0001]\], and even maternal and infant death \[[@CIT0002], [@CIT0003]\]. The World Health Organization (WHO) recommends several interventions to control malaria during pregnancy, namely effective case management, long-lasting insecticidal nets, and intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) from the second trimester onward \[[@CIT0004]\].

The protective efficacy of IPTp-SP against malaria infection depends on the number of IPTp-SP doses administered, which in turn depends on antenatal clinic (ANC) attendance. In many sub-Saharan African countries, both ANC and IPTp-SP coverage remains low \[[@CIT0005], [@CIT0006]\]. In addition, sulfadoxine-pyrimethamine (SP) resistance is increasing and may have an impact on current IPTp-SP policy \[[@CIT0007]\]. In West Africa, where SP resistance is low \[[@CIT0008]\], an alternative strategy of intermittent screening and treatment in pregnancy (ISTp) was noninferior to IPTp-SP in preventing low birth weight, anemia, and placental malaria. In southeast Africa, it was associated with a higher malaria risk, possibly because of the low sensitivity of currently available rapid diagnostic tests (RDTs) in detecting low-density infections \[[@CIT0009], [@CIT0010]\]. WHO does not recommend ISTp alone. However, there is the need to both improve ANC coverage and protect pregnant women against malaria between ANC visits. ISTp at the village level could be beneficial if given in addition to IPTp-SP at ANC. Community health workers (CHWs) have been trained in many sub-Saharan African countries to perform community case management of malaria, and could be trained to encourage pregnant women to attend the ANC and to systematically screen and treat them between ANC visits \[[@CIT0011]\].

A cluster-randomized controlled trial was designed to establish whether adding community scheduled malaria screening and treatment (CSST) by CHWs to standard IPTp-SP would further reduce placental malaria compared to IPTp-SP alone \[[@CIT0012]\].

METHODS {#s6}
=======

Study Sites and Participants {#s7}
----------------------------

A description of the study methods has been published elsewhere \[[@CIT0012]\]. The study was implemented in 3 West African countries: Burkina Faso (Nanoro health district), The Gambia (Upper River region), and Benin (Glo-Djigbe, Zinvie, and Ze districts). In Burkina Faso and The Gambia, malaria is highly seasonal (July--December), whereas in Benin it is perennial with peaks during the rainy seasons (April--July and October--November). In all villages, community consent was obtained after sensitization meetings. All resident pregnant women were invited to participate after individual signed informed consent.

Randomization and Blinding {#s8}
--------------------------

Thirty villages (clusters) (village population: 1000--2000) with CHWs in each country were randomly selected from all eligible clusters. Distance from the center of each village to the nearest health facility was calculated and used to group the clusters into 3 distance categories. Randomization was performed using computer-based randomization (Stata software, StataCorp, College Station, Texas) and was stratified by the 3 distance categories.

Procedures {#s9}
----------

### At the Antenatal Clinic {#s10}

Recruitment was done at first ANC ([Figure 1](#F1){ref-type="fig"}). All women had a physical examination, a blood slide, and a blood sample on filter paper. Information on health and socioeconomic factors was also collected. Pregnant women in the second or third trimester were given their first IPTp-SP and their second dose booked in. A health assessment was carried out at each ANC visit. Suspected malaria cases had an RDT (SD Bioline; specificity 99.5%) and women testing positive were treated with artemether-lumefantrine (AL).

![Schedule of events, updated from the Trial protocol paper \[[@CIT0012]\]. Abbreviations: ANC, antenatal clinic; IPTp, intermittent preventive treatment in pregnancy.](ciy52201){#F1}

### Community Health Worker Home Visits in the Intervention Arm {#s11}

CHWs in the intervention arm were trained in malaria case management and malaria in pregnancy, including the benefit of early ANC attendance and IPTp-SP. CHWs were asked to continuously identify all pregnant women and encourage them to attend the ANC as early as possible. Thereafter, at monthly intervals up to the last week of gestation, CHWs performed an RDT at home visits and collected a blood slide, regardless of malaria symptoms. They gave AL to all positive women. Severely ill women were referred to the health center for further care. The CHWs in the control villages did not take part in any of the study training.

### At Time of Delivery for All Communities {#s12}

A blood sample for hemoglobin measurement and on slide and filter paper for later parasitological diagnosis was collected just before delivery, and a placenta biopsy was collected at delivery. Current health status and birth outcomes were collected. All newborns were physically examined and weighed on digital scales immediately after delivery. Gestational age was estimated using the Ballard score \[[@CIT0013]\].

### Laboratory Methods {#s13}

Giemsa-stained thick blood films were read by 2 experienced microscopists, with discrepancies resolved by a third one \[[@CIT0012]\]. Maternal hemoglobin was measured using Hb301 Hemocue (Radiometer Group, Sweden). Blood spots on filter paper were analyzed by *Plasmodium falciparum* diagnostic polymerase chain reaction (PCR) \[[@CIT0014], [@CIT0015]\].

Details of biopsy methods can be found elsewhere \[[@CIT0012]\]. Placental biopsy slides were read by trained microscopists and classified as infected (acute: parasites and malaria pigment absent; chronic: parasites and malaria pigment; or past: only malaria pigment) or not infected (no parasites or pigment) \[[@CIT0016]\].

Outcomes {#s14}
--------

The primary outcome was placental malaria (any category). However, in Benin, rumors on placental biopsies had a negative impact on recruitment and, after discussions with the data and safety monitoring board (DSMB) and the local ethics committee, it was decided to collect only peripheral blood. Secondary endpoints were maternal anemia (hemoglobin \<11 g/dL) at delivery, maternal *P. falciparum* peripheral infection at delivery (PCR) and during pregnancy (microscopy), low birth weight (\<2500 g), IPTp-SP coverage, the number of ANC visits, and the number of IPTp-SP doses. Serious adverse events (SAEs) were defined as any untoward medical occurrence that resulted in death, hospitalization, persistent or significant disability/incapacity, or congenital anomaly/birth defect or that was life-threatening. All SAEs were reported to the DSMB.

Statistical Analysis {#s15}
--------------------

It was assumed that the intervention would decrease placental malaria from 15% to 10.5%, with a coefficient of variation of 0.15. Within each country, 15 clusters, each with 60 pregnant women per arm, would be able to detect a significant difference with 80% power and at the 5% significance level. Thus, 90 clusters with a total of 5400 women were required. All data were double entered using OpenClinica databases.

The primary endpoint (prevalence of placental malaria) was examined with logistic regression. Random effects for trial cluster were used to account for intracluster correlation. An analysis of the primary endpoint adjusted for season, gravidity, and number of SP and AL doses was carried out. All other binary endpoints were examined with random effects logistic regression. Count data were analyzed with mixed effects Poisson regression and continuous data were analyzed with mixed effects linear regression.

Ethical Approval {#s16}
----------------

The study was done in accordance with the principles set forth in the Declaration of Helsinki and the International Conference on Harmonisation Tripartite Guidelines for Good Clinical Practice. Independent trial monitors visited each site throughout the study to ensure compliance with Good Clinical Practice standards. The trial was approved by the Gambia Government/Medical Research Council Joint Ethics Committee (reference number SCC1336), the Comité d'Ethique Institutionnel du Centre Muraz in Burkina Faso (reference number A20-2013/CE-CM), and the Comité National d'Ethique pour la Recherche en Santé in Benin (reference number 0126/MS /DC/SGM/DFR/CNERS/SA). A DSMB to review the trial procedures and results was set up. The trial is registered at Current Controlled Trials: ISRCTN37259296 (5 July 2013), and ClinicalTrials.gov: NCT01941264 (10 September 2013).

RESULTS {#s17}
=======

Recruitment, Baseline Characteristics, and Follow-up {#s18}
----------------------------------------------------

Between November 2013 and November 2015, 4731 pregnant women were recruited ([Figure 2](#F2){ref-type="fig"} and [Supplementary Figure 1*A--C*](#sup1){ref-type="supplementary-material"}), with Benin having recruited only half of the expected sample size. Loss to follow-up was low in The Gambia (113/1960 \[5.8%\]) and in Burkina Faso (62/1800 \[3.4%\]) but high in Benin (290/971 \[29.9%\]). Overall, 4266 (90.2%) women completed the follow-up and delivered in study ([Figure 2](#F2){ref-type="fig"}).

![Flowchart of the cohort of pregnant women enrolled in the study. Primary outcome is placental malaria for the Burkina Faso and The Gambia study sites and maternal peripheral infection at time of delivery for the Benin study site.](ciy52202){#F2}

In each country, baseline characteristics between intervention and control groups were similar. Use of insecticide-treated bed nets was \>70%, and malaria prevalence was 5.3% in The Gambia (101/1888), 27.9% in Burkina Faso (501/1797), and 30.0% in Benin (288/959). About 20% were primigravidae ([Table 1](#T1){ref-type="table"}).

###### 

Baseline Characteristics of Study Clusters at Start of the Trial, by Country

  Characteristic                                             Burkina Faso   Gambia     Benin                                                                           
  ---------------------------------------------------------- -------------- ---------- ------- ---------- ----- ---------- ----- ------------ ----- ------------ ----- ----------
  No. of clusters                                            15             ...        15      ...        15    ...        15    ...          15    ...          15    ...
   Median No. of women per cluster (IQR)                     60             (60--60)   60      (60--60)   69    (61--98)   67    (53--95)     41    (19--55)     48    (27--62)
   Median age, y (IQR)                                       25             (20--30)   26      (21--30)   25    (20--29)   25    (20--29.5)   25    (21--29.5)   25    (20--30)
  Ethnic group                                                                                                                                                         
   Mandinka                                                  ...            ...        ...     ...        238   (25.0)     332   (32.9)       ...   ...          ...   ...
   Fula                                                      ...            ...        ...     ...        199   (20.9)     98    (9.7)        ...   ...          ...   ...
   Serahuleh                                                 ...            ...        ...     ...        510   (53.6)     577   (57.2)       ...   ...          ...   ...
   Mossi                                                     854            (94.9)     794     (88.2)     ...   ...        ...   ...          ...   ...          ...   ...
   Aizo/Ouemenou                                             ...            ...        ...     ...        ...   ...        ...   ...          389   (90.7)       473   (87.27)
   Other                                                     46             (5.1)      106     (11.8)     5     (0.5)      1     (0.1)        40    (9.3)        69    (12.73)
  Median gestational age, wk, at time of recruitment (IQR)   22             (20--24)   22      (20--24)   20    (17--22)   20    (17--22)     20    (18--24)     20    (18--24)
  No. of previous pregnancies                                                                                                                                          
   0                                                         194            (21.6)     185     (20.6)     162   (17.1)     226   (22.4)       90    (21.0)       117   (21.6)
   1                                                         153            (17.0)     136     (15.1)     175   (18.4)     172   (17.1)       84    (19.6)       104   (19.2)
   2                                                         169            (18.8)     145     (16.1)     144   (15.2)     136   (13.5)       67    (15.6)       92    (17.0)
   3                                                         136            (15.1)     141     (15.7)     142   (15.0)     143   (14.2)       70    (16.3)       83    (15.3)
   ≥4                                                        248            (27.6)     293     (32.6)     327   (34.4)     330   (32.8)       118   (27.5)       146   (26.9)
  Marital status                                                                                                                                                       
   Married                                                   759            (86.0)     832     (94.7)     930   (97.7)     987   (98.0)       206   (48.0)       245   (45.2)
   Not married                                               124            (14.0)     47      (5.4)      22    (2.3)      20    (2.0)        223   (52.0)       297   (54.8)
  Religion                                                                                                                                                             
   Christianity                                              521            (58.0)     466     (52.0)     ...   ...        ...   ...          386   (90.0)       499   (92.1)
   Islam                                                     215            (23.9)     306     (34.2)     935   (98.2)     986   (97.9)       ...   ...          ...   ...
   Traditional African religion                              134            (14.9)     111     (12.4)     ...   ...        ...   ...          ...   ...          ...   ...
   Other                                                     28             (4.9)      13      (1.5)      17    (1.8)      21    (2.1)        43    (10.0)       43    (7.9)
  Woman's occupation                                                                                                                                                   
   Housewife                                                 818            (91.4)     802     (90.3)     109   (11.5)     122   (12.2)       114   (26.6)       156   (29.1)
   Farmer/herder/gardener                                    47             (5.3)      67      (7.6)      719   (75.8)     760   (75.7)       42    (9.8)        46    (8.6)
   Sell at market/shopkeeper                                 ...            ...        ...     ...        62    (6.5)      65    (6.5)        144   (33.6)       151   (28.1)
   Childcare/domestic helper                                 ...            ...        ...     ...        45    (4.7)      50    (5.0)        ...   ...          ...   ...
   Seamstress                                                ...            ...        ...     ...        ...   ...        ...   ...          65    (15.2)       95    (17.7)
   Hairdresser                                               ...            ...        ...     ...        ...   ...        ...   ...          44    (10.3)       57    (10.6)
   Other                                                     30             (3.4)      19      (2.1)      14    (1.5)      7     (0.7)        19    (4.4)        32    (6.0)
  Husband's occupation                                                                                                                                                 
   Farmer/herdsman/fisherman/ gardener                       707            (93.3)     789     (94.8)     578   (63.2)     591   (61.2)       103   (50.2)       103   (42.2)
   Bricklayer/carpenter/welder                               ...            ...        ...     ...        36    (3.9)      46    (4.8)        20    (9.8)        28    (11.5)
   Sell at market/shopkeeper                                 ...            ...        ...     ...        84    (9.2)      66    (6.8)        ...   ...          ...   ...
   Imam/marabout/VHW                                         ...            ...        ...     ...        23    (2.5)      20    (2.1)        ...   ...          ...   ...
   Other                                                     51             (6.7)      43      (5.2)      73    (8.0)      118   (12.2)       61    (29.8)       80    (32.8)
   Traveler                                                  ...            ...        ...     ...        105   (11.5)     107   (11.1)       ...   ...          ...   ...
   Driver/motorbike driver                                   ...            ...        ...     ...        ...   ...        ...   ...          21    (10.2)       33    (13.5)
   Teacher                                                   ...            ...        ...     ...        15    (1.6)      17    (1.8)        ...   ...          ...   ...
  Slept under treated net last night                                                                                                                                   
   Yes                                                       657            (73.2)     706     (78.7)     755   (80.2)     726   (72.9)       312   (72.7)       406   (74.9)
   No                                                        158            (17.6)     125     (13.9)     114   (12.1)     126   (12.7)       84    (19.6)       103   (19.0)
   Do not have one                                           76             (8.5)      61      (6.8)      73    (7.6)      144   (14.5)       33    (7.7)        33    (6.1)
   Don't know if have one                                    6              (0.7)      5       (0.6)      ...   ...        ...   ...          ...   ...          ...   ...
  Malaria positive by microscopy at recruitment                                                                                                                        
   No                                                        640            (71.3)     656     (73.0)     870   (95.2)     917   (94.2)       300   (71.3)       371   (69.0)
   Yes                                                       258            (28.7)     243     (27.0)     44    (4.8)      57    (5.9)        121   (28.7)       167   (31.0)

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: IQR, interquartile range; VHW, village health workers.

Most women in the intervention arm had at least 1 CSST by CHWs, with coverage higher in Burkina Faso (860/900 \[96%\]) and The Gambia (978/1008 \[97%\]) compared with Benin (474/542 \[87.5%\]). Overall, CHWs performed 7236 CSSTs, with an average of 3--4 home visits per woman ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). The mean number of slides per woman was significantly higher in the intervention than in the control group (Burkina Faso: means ratio \[MR\], 1.62 \[95% confidence interval {CI}, 1.50--1.74\]; The Gambia: MR, 2.08 \[95% CI, 1.98--2.19\]; Benin: MR, 2.04 \[95% CI, 1.87--2.23\]) (*P* \< .001). Malaria infection was detected by RDT at least once for 75 (3.8%) women in The Gambia, 164 (16.9%) in Benin, and 568 (31.6%) in Burkina Faso, and most received AL ([Table 2](#T2){ref-type="table"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). The number of pregnant women diagnosed with a malaria infection was significantly higher in the intervention arm than in the control arm (*P* \< .01 for all study sites). A high proportion of infected women received AL, with no difference between study arms in Burkina Faso and The Gambia. In Benin, the proportion of treated women was higher in the intervention arm (172/191 \[90.0%\]) than in the control arm (14/33 \[42.4%\]) (odds ratio \[OR\], 1.71 \[95% CI, .99--2.94\]; *P* = .055).

###### 

Total Number of Malaria Cases Diagnosed at Home Visits (Intervention Arm Only) and Antenatal Clinic Visits (Both Arms) by Rapid Diagnostic Test and Total Artemether-Lumefantrine Treatments Given During Study for All Countries

  Cases                                               Overall   Control   Intervention   OR/RR   95% CI   *P* Value                           
  --------------------------------------------------- --------- --------- -------------- ------- -------- ----------- --------- ------------- --------
  Burkina Faso                                                                                                                                
   Total No. of positive malaria cases^a^             994       ...       388            ...     606      ...         1.56^b^   1.13--2.15    .006
   Total No. of AL treatment given (% out of cases)   761       76.6      302            77.8    459      75.7        1.08^b^   .94--1.25     .274
   Total No. of women tested positive at least once   568       31.6      237            26.3    331      36.8        1.67^c^   1.22--2.30    .002
  The Gambia                                                                                                                                  
   Total No. of positive malaria cases^a^             87        ...       15             ...     72       ...         4.55^b^   2.48--8.34    \<.001
   Total No. of AL treatment given (% out of cases)   71        81.6      12             80.0    59       81.9        1.23^b^   .66--2.29     .515
   Total No. of women tested positive at least once   75        3.8       15             1.6     60       6.0         3.94^c^   2.05--7.59    \<.001
  Benin                                                                                                                                       
   Total No. of positive malaria cases^a^             224       ...       33             ...     191      ...         4.67^b^   2.93--7.44    \<.001
   Total No. of AL treatment given (% out of cases)   186       83.0      14             42.4    172      90.1        1.71^b^   .99--2.94     .055
   Total No. of women tested positive at least once   164       16.9      20             4.7     144      26.6        7.53^c^   4.49--12.64   \<.001

Abbreviations: AL, artemether-lumefantrine; CI, confidence interval; OR, odds ratio; RR, rate ratio.

^a^Woman can be positive more than once during pregnancy.

^b^RRs obtained from Poisson regression models.

^c^ORs obtained from logistic regression models.

The Effect of the Intervention on Placenta Malaria {#s19}
--------------------------------------------------

Data from placental biopsies were available for 88% (3171/3585) of deliveries in Burkina Faso and The Gambia. There was no difference between intervention and control arms in terms of placenta malaria or for different categories of infection ([Table 3](#T3){ref-type="table"}), and this did not change after adjusting for season of birth, parity, and number of IPTp-SP administered (adjusted OR \[aOR\], 1.06 \[95% CI, .78--1.44\]; *P* = .72) ([Table 4](#T4){ref-type="table"}). Similar results were observed at country level ([Supplementary Tables 2 and 3](#sup1){ref-type="supplementary-material"}).

###### 

Placental Malaria in Burkina Faso and The Gambia

  Histology                                  Control   Intervention   Odds Ratio   95% CI   *P* Value               
  ------------------------------------------ --------- -------------- ------------ -------- ----------- ----------- ------
  No. with biopsy data                       1544                     1622                  ...         ...         ...
  Placental histology                                                                                               
   Any infection (acute, chronic, or past)   494       32             533          33       1.09        .80--1.48   .588
   No infection                              1050      68             1089         67       ...         ...         ...
   Active infection (acute or chronic)       64        4              65           4        0.99        .66--1.49   .974
   No active infection                       1480      96             1557         96       ...         ...         ...
   Past or chronic infection                 472       31             509          31       1.09        .81--1.46   .571
   No past or chronic infection              1072      69             1113         69       ...         ...         ...

Abbreviation: CI, confidence interval.

###### 

Overall Adjusted Analysis for Placental Malaria in The Gambia and Burkina Faso

  Characteristic               No.    Positive, No. (%)   Unadjusted OR   95% CI        *P* Value   Adjusted OR^a^   95% CI       *P* Value
  ---------------------------- ------ ------------------- --------------- ------------- ----------- ---------------- ------------ -----------
  Arm                                                                                                                             
   Intervention                1621   533 (33)            ...             ...           ...         ...              ...          ...
   Control                     1543   494 (32)            1.09            .80--1.48     .588        1.06             .78--1.44    .722
  Seasonality                                                                                                                     
   Delivery in rainy reason    1684   440 (26)            0.71            .59--.84      \<.001      0.59             .49--.71     \<.001
   Delivery in dry season      1480   587 (40)            1               ...           ...         ...              ...          ...
  Gravida                                                                                                                         
   First or second pregnancy   1124   451 (40)            ...             ...           ...         ...              ...          ...
   \>2 pregnancies             2040   576 (28)            0.47            .39--.56      \<.001      0.47             .39--.57     \<.001
  No. of SP doses                                                                                                                 
   0                           9      1 (11)              0.90            .10--.77      ...         0.54             .06--5.14    ...
   1                           496    140 (28)            1               ...           ...         1                ...          ...
   2                           1892   571 (30)            0.87            .66--1.14     ...         0.85             .65--1.12    ...
   3                           460    203 (44)            0.41            .29--.57      ...         0.37             .26--.53     ...
   4                           251    95 (38)             0.23            .16--.34      ...         0.23             .15--.34     ...
   5                           50     15 (30)             0.15            .08--.30      ...         0.13             .07--.27     ...
   6                           6      2 (33)              0.15            .03--.90      \<.001      0.10             .01--.64     \<.001
  No. of AL treatments given                                                                                                      
   0                           2651   695 (26)            1               ...           ...         1                ...          ...
   1                           364    223 (61)            2.10            1.62--2.72    ...         2.01             1.53--2.64   ...
   2                           75     75 (70)             2.60            1.66--4.08    ...         1.86             1.15--3.02   ...
   ≥3                          34     34 (81)             4.52            2.01--10.15   \<.001      2.98             1.28--6.95   \<.001

Data are shown for any infection (acute, chronic, or past).

Abbreviations: AL, artemether-lumefantrine; CI, confidence interval; OR, odds ratio; SP, sulfadoxine-pyrimethamine.

^a^Adjusted for all other variables in the table.

The Effect of the Intervention on Other Secondary Outcomes at Delivery {#s20}
----------------------------------------------------------------------

There was no difference between arms in peripheral maternal infection (OR, 0.97 \[95% CI, .78--1.21\]; *P* = .7), even after adjusting for several factors (aOR, 0.92 \[95% CI, .74--1.15\]; *P* = .4) ([Table 5](#T5){ref-type="table"}; country-specific data in [Supplementary Table 3](#sup1){ref-type="supplementary-material"}). Anemia (OR, 1.09 \[95% CI, .92--1.28\]; *P* = .3; [Table 6](#T6){ref-type="table"} and [Supplementary Table 4](#sup1){ref-type="supplementary-material"}), mean hemoglobin (mean difference, 0.01 \[95% CI, --.29 to .31\]; *P* = .9), low birth weight (OR, 1.06 \[95% CI, .82--1.38\]; *P* = .6; [Table 7](#T7){ref-type="table"} and [Supplementary Table 5](#sup1){ref-type="supplementary-material"}), and adverse pregnancy outcomes ([Table 8](#T8){ref-type="table"} and [Supplementary Table 6](#sup1){ref-type="supplementary-material"}) did not differ between study arms. Nevertheless, in Burkina Faso, the odds of miscarriage tended to be higher in the intervention arm (OR, 4.54 \[95% CI, .98--21.05\]; *P* = .054; [Supplementary Table 6*A*](#sup1){ref-type="supplementary-material"}). Among these women, 3 had a malaria infection at least once during pregnancy (2 in the intervention arm and 1 in the control arm), and 2 received 1 course of AL (1 in each arm), with no drug-related serious adverse event recorded. There was no evidence that taking AL during pregnancy was associated with any adverse pregnancy outcome (at least 1 course of AL: OR, 0.82 \[95% CI, .35--1.93\]; *P* = .656).

###### 

Overall Adjusted Analysis for Maternal Peripheral Infection at Delivery (as Measured by Polymerase Chain Reaction)

  Characteristic               No.    Positive, No. (%)   Unadjusted OR   95% CI       *P* Value   Adjusted OR^a^   95% CI       *P* Value
  ---------------------------- ------ ------------------- --------------- ------------ ----------- ---------------- ------------ -----------
  Arm                                                                                                                            
   Intervention                1951   208 (10.66)         1               ...          ...         1                ...          ...
   Control                     1826   200 (10.95)         0.97            .78--1.21    .798        0.92             .74--1.15    .456
  Seasonality                                                                                                                    
   Delivery in rainy reason    1796   125 (6.96)          2.94            2.34--3.69   \<.001      2.84             2.25--3.58   \<.001
   Delivery in dry season      1981   283 (14.29)         1               ...          ...         1                ...          ...
  Gravida                                                                                                                        
   First or second pregnancy   1329   165 (12.42)         1               ...          ...         1                ...          ...
   \>2 pregnancies             2448   243 (9.93)          0.76            .61--.84     .012        0.83             .66--1.04    .101
  No. of AL treatments given                                                                                                     
   0                           3107   273 (8.79)          1               ...          ...         1                ...          ...
   1                           478    88 (18.41)          1.43            1.09--1.88   ...         1.33             1.00--1.77   ...
   2                           145    33 (22.76)          1.76            1.16--2.66   ...         1.76             1.13--2.73   ...
   ≥3 (max 6)                  47     14 (29.79)          2.35            1.23--4.48   \<.001      2.26             1.15--4.47   .006
  No. of SP doses                                                                                                                
   0                           4      0 (0)               ...             ...          ...         ...              ...          ...
   1                           677    83 (12.26)          1               ...          ...         1                ...          ...
   2                           2192   219 (9.99)          0.72            .54--.96     ...         0.74             .55--.98     ...
   3                           531    50 (9.42)           0.30            .20--.44     ...         0.37             .24--.56     ...
   4                           298    46 (15.44)          0.47            .31--.71     ...         0.55             .36--.85     ...
   5                           67     9 (13.43)           0.39            .18--.84     ...         0.44             .20--.94     ...
   6                           8      1 (12.50)           0.38            .05--3.15    \<.001      0.28             .03--2.42    \<.001

Abbreviations: AL, artemether-lumefantrine; CI, confidence interval; OR, odds ratio; SP, sulfadoxine-pyrimethamine.

^a^Adjusted for all other variables in the table.

###### 

Anemia at Delivery, by Study Arm (All Countries)

  Characteristic               No.    Anemic^a^, No. (%)   OR     95% CI       *P* Value   Adjusted   95% CI       *P* Value
  ---------------------------- ------ -------------------- ------ ------------ ----------- ---------- ------------ -----------
  Arm                                                                                                              
   Intervention                1989   861 (43)             1      ...          ...         1          ...          ...
   Control                     2167   979 (45)             1.08   .92--1.28    .351        1.09       .92--1.28    .321
  Seasonality                                                                                                      
   Delivery in rainy season    2194   1089 (50)            1      ...          ...         1          ...          ...
   Delivery in dry season      1962   751 (38)             0.72   .63--.82     \<.001      0.73       .64--.83     \<.001
  Gravida                                                                                                          
   First or second pregnancy   1480   634 (43)             1      ...          ...         1          ...          ...
   \>2 pregnancies             2674   1205 (45)            1.13   .99--1.30    .078        1.14       1.00--1.32   .052
  No. of AL treatments given                                                                                       
   0                           3458   1623 (47)            1      ...          ...         1          ...          ...
   1                           505    147 (29)             0.85   .68--1.06    ...         0.83       .66--1.04    ...
   2                           146    56 (38)              1.54   1.07--2.21   ...         1.58       1.09--2.28   ...
   ≥3 (max 6)                  47     14 (30)              1.23   .64--2.35    ...         1.26       .65--2.41    ...
                                                                               .029                                .017
  No. of SP doses                                                                                                  
   1                           754    407 (54)             1      ...          ...         1          ...          ...
   2                           2454   1187 (48)            0.80   .67--.95     ...         0.81       .68--.96     ...
   3                           549    147 (27)             0.68   .52--.89     ...         0.72       .54--.95     ...
   4                           312    74 (24)              0.70   .50--.98     ...         0.73       .52--1.02    ...
   5                           69     20 (29)              0.94   .53--1.66    ...         0.99       .99--1.75    ...
   6                           8      2 (25)               0.76   .15--3.86    ...         0.78       .15--4.06    ...
                                                                               .022                                .065

Abbreviations: AL, artemether-lumefantrine; CI, confidence interval; OR, odds ratio; SP, sulfadoxine-pyrimethamine.

^a^Anemia defined as hemoglobin level \<11 g/dL.

###### 

Low Birth Weight, by Study Arm (All Countries)

  Characteristic               No.    LBW, No. (%)   OR     95% CI       *P* Value   Adjusted   95% CI      *P* Value
  ---------------------------- ------ -------------- ------ ------------ ----------- ---------- ----------- -----------
  Arm                                                                                                       
   Intervention                2127   219 (10)       1      ...          ...         1          ...         ...
   Control                     1950   201 (10)       1.06   .82--1.38    .643        1.06       .81--1.38   .695
  Seasonality                                                                                               
   Delivery in rainy season    2159   213 (10)       1      ...          ...         1          ...         ...
   Delivery in dry season      1918   207 (11)       1.09   .89--1.34    .417        1.13       .92--1.40   .247
  Gravida                                                                                                   
   First or second pregnancy   1456   212 (15)       1      ...          ...         1          ...         ...
   \>2 pregnancies             2619   208 (8)        0.50   .40--.61     \<.001      0.50       .40--.61    \<.001
  No. of AL treatments given                                                                                
   0                           3393   334 (10)       1      ...          ...         1          ...         ...
   1                           493    62 (13)        1.36   1.00--1.85   ...         1.24       .91--1.71   ...
   2                           144    16 (11)        1.18   .68--2.04    ...         0.88       .50--1.55   ...
   ≥3 (max 6)                  47     8 (17)         1.87   .84--4.12    ...         1.34       .62--3.12   ...
                                                                         .128                               .429
  No. of SP doses                                                                                           
   1                           731    111 (15)       1      ...          ...         1          ...         ...
   2                           2415   230 (10)       0.55   .28--6.96    ...         0.54       .42--.70    ...
   3                           539    49 (9)         0.45   .43--.71     ...         0.44       .30--.66    ...
   4                           305    21 (7)         0.32   .30--.66     ...         0.33       .19--.55    ...
   5                           69     7 (10)         0.46   .19--.54     ...         0.43       .18--.55    ...
   6                           0      0 (0)          ...    ...          ...         ...        ...         ...
                                                                         \<.001                             \<.001

Abbreviations: AL, artemether-lumefantrine; CI, confidence interval; LBW, low birth weight; OR, odds ratio; SP, sulfadoxine-pyrimethamine.

###### 

Adverse Outcome of Pregnancy, by Study Arm (All Countries)

  Outcome                                                Control   Intervention   OR/Mean Difference   95% CI   *P* Value                  
  ------------------------------------------------------ --------- -------------- -------------------- -------- ----------- -------------- ------
  Anemia                                                                                                                                   
   Hb \<11 g/dL                                          861       43             979                  45       1.09^a^     .92--1.28      .351
   Hb ≥11 g/dL                                           1128      57             1188                 55       ...         ...            ...
  Mean Hb (SD)                                           11.15     0.71           11.14                0.73     0.01^b^     --.29 to .31   .944
  Low birth weight (\<2500 g)                                                                                                              
   \<2500                                                201       10             219                  10       1.06^a^     .82--1.38      .643
   ≥2500                                                 1749      90             1908                 90       ...         ...            ...
  Mean birth weight, kg (SD)                             2.98      0.17           2.94                 0.14     0.04^b^     --.04 to .10   .254
  Adverse pregnancy outcomes                                                                                                               
   Congenital abnormalities                              16        0.8            29                   1.3      1.70^a^     .92--3.15      .089
   Miscarriage                                           16        0.7            16                   0.7      0.98^a^     .45--2.15      .959
   Preterm birth                                         60        3              70                   3        1.06^a^     .68--1.67      .793
   Stillbirth                                            39        2              47                   2        1.05^a^     .64--1.72      .855
   Miscarriage, preterm, or stillbirth                   99        4              116                  5        1.10^a^     .79--1.52      .582
  Deaths                                                                                                                                   
   Perinatal death                                       21        1              24                   1        1.03^a^     .57--1.85)     .933
   Maternal death                                        6         0.3            3                    0.1      0.46^a^     .12--1.86)     .279
  Perinatal death, miscarriage, preterm, or stillbirth   114       5              131                  5        1.07^a^     .79--1.45)     .654

Abbreviations: CI, confidence interval; Hb, hemoglobin; OR, odds ratio; SD, standard deviation.

aOR.

bMean difference.

There were 9 maternal deaths (6 in the control arm and 3 in the intervention arm) and 45 perinatal deaths that occurred at time of delivery (21 in control vs 24 in intervention arm). Causes attributed to the SAEs, including maternal and perinatal death, are reported in [Supplementary Table 8](#sup1){ref-type="supplementary-material"}.

ANC Attendance and IPTp-SP Uptake During Pregnancy {#s21}
--------------------------------------------------

Antenatal clinic attendance (scheduled visits) was significantly higher in the intervention arm in Burkina Faso but not in The Gambia and Benin ([Table 9](#T9){ref-type="table"} and [Supplementary Table 7](#sup1){ref-type="supplementary-material"}). However, IPTp-SP coverage (ie, mean number of doses and percentage of women who received at least 2 or 4 doses) was not significantly different between intervention and control arms.

###### 

Summary Estimates of the Effect of the Intervention on Antenatal Clinic Attendance and Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine Coverage, by Country^a^

  Intervention                           Burkina Faso   The Gambia   Benin                                                      
  -------------------------------------- -------------- ------------ ------- --------- ----------- ------ --------- ----------- ------
  ANC visits                                                                                                                    
   At least 2 scheduled visits           ...            ...          ...     1.03^b^   .66--1.62   .881   0.88^b^   .63--1.24   .471
   At least 4 scheduled visits           1.62^b^        1.02--2.59   .041    ...       ...         ...    ...       ...         ...
   Mean No. of scheduled visits (SD)     1.08^c^        1.00--1.17   .045    1.00^c^   .93--1.09   .912   0.98^c^   .93--1.04   .484
   Mean No. of unscheduled visits (SD)   0.90^c^        .63--1.30    .589    1.34^c^   .80--2.22   .266   1.07^c^   .61--1.89   .81
   Mean No. of any ANC visits (SD)       1.06^c^        .96--1.16    .258    1.07c     .90--1.27   .445   0.99^c^   .91--1.07   .781
  IPTp-SP coverage                                                                                                              
   Mean No. of SP doses                  1.04^c^        .97--1.10    .294    1.01^c^   .97--1.05   .611   0.98^c^   .92--1.03   .387
   At least 2 doses of SP                1.29^b^        .96--1.73    .093    1.01^b^   .70--1.46   .938   0.87^b^   .62--1.22   .418
   At least 4 doses of SP                1.14^b^        .76--1.72    .517    ...       ...         ...    ...       ...         ...

Abbreviations: ANC, antenatal clinic; CI, confidence interval; IPTp-SP, intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine; IRR, incidence rate ratio; OR, odds ratio; SD, standard deviation; SP, sulfadoxine-pyrimethamine.

^a^IPTp-SP policies vary between countries; thus, data are not pooled.

bOR.

cIRR.

The Effect of IPTp-SP on Pregnancy Outcomes {#s22}
-------------------------------------------

Increasing number of IPTp-SP doses was associated with a significantly lower risk of placenta malaria ([Table 4](#T4){ref-type="table"}), mainly because of Burkina Faso where 49.2% (886/1800) of women had received ≥3 IPTp-SP doses ([Supplementary Table 3*A*](#sup1){ref-type="supplementary-material"}), whereas in The Gambia this figure was only 3.7% (73/1960) ([Supplementary Table 3*B*](#sup1){ref-type="supplementary-material"}). Placenta malaria occurred significantly less during the rainy than the dry season (aOR, 0.59 \[95% CI, .49--.71\]; *P* \< .001), and was more frequent with increasing number of AL treatments ([Table 4](#T4){ref-type="table"}).

Increasing number of IPTp-SP doses tended to decrease the risk of anemia at delivery (*P* = .06), whereas increasing number of AL treatments had the opposite effect (*P* = .02) ([Table 6](#T6){ref-type="table"} and [Supplementary Table 4](#sup1){ref-type="supplementary-material"}). Similarly, the risk of low birth weight decreased significantly with the increasing number of IPTp-SP doses (*P* \< .001; [Table 7](#T7){ref-type="table"} and [Supplementary Table 5](#sup1){ref-type="supplementary-material"}).

DISCUSSION {#s23}
==========

Adding CSST by CHWs to the standard IPTp-SP at ANC did not reduce the risk of placental malaria or peripheral malaria infection at delivery. The intervention also aimed at increasing ANC attendance, particularly in early pregnancy, and at identifying and treating infections between scheduled ANC visits. Scheduled ANC attendance did improve in Burkina Faso, suggesting that the intervention had the expected effect. During the trial, the 2013 WHO recommendations of at least 4 ANC visits and of administering IPTp-SP at each of them \[[@CIT0017]\] had been implemented in Burkina Faso, with some women having as many as 6--7 scheduled ANC visits. In The Gambia and Benin, the national policy was still 2 scheduled visits; thus, we did not expect an increase in the number of ANC visits but rather an increase in coverage of 2 ANC visits. ANC attendance remained extremely low in Benin, where only slightly more than half of the women had 2 visits, and this may reflect the general poor attendance in southern Benin. In The Gambia, ANC attendance was already high, with 80% of the women attending at least 2 scheduled visits, and this may explain why the intervention did not have the expected effect.

In all countries, the higher number of malaria infections diagnosed in the intervention group and the high proportion of malaria-positive women treated with AL indicate that CHWs implemented the intervention according to the instructions received. In Burkina Faso, RDT sensitivity and specificity performed by CHWs and compared to microscopy was 81.5% (95% CI, 67.9%--90.2%) and 92.1% (95% CI, 89.9%--93.9%), respectively \[[@CIT0014]\], further confirming CHWs can both correctly use RDTs and adhere to test results and treatment guidelines \[[@CIT0018]\]. Previous studies have shown that CHWs are able to diagnose and treat malaria in children \[[@CIT0019]\] and are able to distribute IPTp to pregnant women \[[@CIT0023]\].

Though the intervention did not have a direct effect on the prevalence of past placenta malaria, probably because of infections before the first ANC visit, one would have expected a reduced risk of active or chronic placenta infections. This was not the case, and this may have been due to low adherence to AL treatment. However, CHWs who visited treated women 3 days after CSST, and 96% of women reported having completed the full course; in contrast, a qualitative study carried out in the same study area reported low adherence to antimalarial treatment by pregnant women despite good knowledge about malaria in pregnancy \[[@CIT0024]\].

Increasing doses of IPTp-SP significantly decreased the risk of placental malaria. This effect was mainly seen in Burkina Faso, where women received up to 6 IPTp-SP doses. In The Gambia and Benin, the large majority of women had taken only 2 IPTp-SP doses and in both countries malaria prevalence was lower than in Burkina Faso. In these 2 countries, CSST should have had some effect as the time between IPTp-SP doses was longer than in Burkina Faso, so diagnosing and treating infections during this period should have been beneficial. Malaria screening by the CHWs was done with an RDT whose detection threshold is at most 200 parasites/μL \[[@CIT0025]\]. However, the large majority of infections during pregnancy are asymptomatic, with low parasite densities, often not detected by microscopy or RDT \[[@CIT0026]\]. Therefore, measurements of the efficacy of intermittent screening and treatment may be limited by the sensitivity of current RDTs \[[@CIT0010]\]. The decreased risk of low birth weight with increasing IPTp-SP doses and the borderline decrease of maternal anemia at delivery confirms the meta-analysis of 7 trials carried out in sub-Saharan Africa that reported a lower risk of low birth weight, maternal anemia, and placental malaria in women who received ≥3 IPTp-SP doses \[[@CIT0027]\]. These results were used to support the WHOs' recommendation of administering IPTp-SP at each ANC, provided the doses are at least a month apart. The current trial data support this recommendation.

Pregnant women in the intervention arm had a higher risk of testing malaria positive, not because they had a higher risk of being infected, but rather because they were tested more frequently. Considering that most infections diagnosed in the intervention arm were treated with AL and that the risk of placenta; malaria increased with the number of AL treatments administered, these infections probably represented a small proportion of all infections acquired during pregnancy and it was the undiagnosed infections that had a significant effect on the occurrence of placenta malaria. Receiving multiple AL treatments is probably a marker of a higher malaria risk. There is some controversy on the importance of low-density malaria infections during pregnancy, associated with anemia, lower mean hemoglobin, low birth weight, and premature births in some studies \[[@CIT0028]\] but not in others \[[@CIT0026]\]. Our results indicate that such infections are important and that, until better diagnostic tests than standard RDTs become available, systematic treatment as many times as possible of all pregnant women until delivery is the best approach.

A major strength of this study was the selection of countries based on their varying malaria endemicity: low (The Gambia) vs high (Burkina Faso and Benin), and with varying degrees of SP resistance (high in Benin and moderate in The Gambia and Burkina Faso), which us enables to generalize study findings to West Africa and possibly other sub-Saharan African countries. The study was powered for individual countries for the overall primary outcome; thus, we were able to at least fully investigate the effect of the intervention on placental malaria for the study sites in The Gambia and Burkina Faso. Unfortunately, this was not possible for Benin.

The significant number of adverse pregnancy outcomes in both study arms highlights the poor access to timely and adequate care for women in rural and remote areas in sub-Saharan Africa. Both maternal anemia and low birth weight (45% and 10%, respectively) were below the West African regional estimates, 56% (95% CI, 46%--62%) \[[@CIT0029]\] and 14% (<https://data.unicef.org/topic/nutrition/low-birthweight/>). Being in a trial may have influenced women's healthcare-seeking behavior, which may explain these lower estimates. There were 45 perinatal deaths and 9 maternal deaths with no difference in mortality between the study arms. Pooling the data together gives a perinatal mortality rate of 10.77 per 1000 live births, and a maternal mortality rate of 215 per 100000 live births. These remain high levels, but comparisons with other sources \[[@CIT0030]\] should be interpreted with caution as they were estimated at time of delivery while the neonatal and maternal mortality usually include days 28 and 42 postpartum, respectively. It is reassuring that no adverse events were associated with AL treatment, providing further safety data for AL treatment in the second and third trimester of pregnancy.

IST has been extensively evaluated as an alternative to IPTp-SP, with mixed results \[[@CIT0008]\]. We decided to combine these 2 interventions, with the aim of providing additional protection against malaria between ANC visits. Despite the significantly higher number of women treated for malaria in the intervention arm, none of the trial outcomes differed between study arms. Treatment with a long-acting artemisinin-based combination therapy such as dihydroartemisinin-piperaquine instead of AL would possibly have had a better outcome. Indeed, the number of AL treatments administered was strongly associated with placental malaria, peripheral infection, and anemia, indicating that treated women had a higher risk of being reinfected over a relatively short period. Such a risk could have been lowered by a treatment with a much longer posttreatment prophylactic period. That the length of the prophylaxis period is more important than treating diagnosed infections is shown by the beneficial effect of increasing IPTp-SP doses on different pregnancy outcomes, including low birth weight. This may change when more sensitive diagnostic tests become available but, for now, increasing the number of IPTp-SP doses given during pregnancy is a priority.

Supplementary Data {#s24}
==================

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.
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